Abstract: A Josephson device includes a first superconducting electrode layer, a barrier layer and a second superconducting electrode layer that are successively stacked. The first and second superconducting electrode layers are made of an oxide superconductor material having (RE)1(AE)2Cu3Oy as a main component, where an element RE is at least one element selected from a group consisting of Y, La, Pr, Nd, Sm, Eu, Gd, Dy, Ho, Er, Tm, Yb and Lu, and an element AE is at least one element selected from a group consisting of Ba, Sr and Ca. The barrier layer is made of a material that includes the element RE, the element AE, Cu and oxygen, where in cations within the material forming the barrier layer, a Cu content is in a range of 35 At. % to 55 At. % and an RE content is in a range of 12 At. % to 30 At. %, and the barrier layer has a composition different from compositions of the first and second superconducting electrode layers.

Abstract: A method for identifying an unknown base sequence present in a target single-stranded nucleic acid utilizing a probe array in which single-stranded nucleic acid probes are arranged as isolated spots on a substrate, where each probe has a base sequence complementary to one of the plural base sequences expected to be the unknown base sequence, and a fluorescence pattern of a sample on the probe array is compared with template patterns to identify the base sequence of the sample.

Abstract: The invention relates to nucleic acid characterisation. In particular, the invention provides a method of sequencing and distinguishing between nucleic acid sequences originating from different sources on an array, the method comprising sequencing of a nucleic acid tag characteristic of the source of the nucleic acid sequences.

Abstract: Provided is a method of detecting a nucleic acid, which enables simple, high-efficiency, and high-precise detection of various genes and may be widely utilized in the fields on the basis of gene detection. Provided is a method of detecting a nucleic acid, which enables a solid-phase universal PCR, solid-phase multiplex PCR, or solid-phase universal multiplex PCR using a nucleic acid array.

Abstract: A method and system for amplifying non-coding RNA, microRNA, and small polynucleotide sequences through the generation of a pool of signature sequences to the target sequences. The target sequences can be amplified through DNA synthesis, RNA synthesis, or the combination of DNA and RNA synthesis. The amplification of signature sequences provides an efficient and reproducible means to determine the presence or absence of the target miRNAs, analyze the quantities of the said target miRNAs, and miRNA profiling. The present invention may also be used for screening for unknown non-coding RNAs, including novel miRNAs.

Abstract: The invention provides a method for determining antigen-specific T cell response in a microarray system consisting of microwells wherein a T-cell preparation is challenged with the antigen and the cytokines thereby released are detected with an immunoassay.

Abstract: According to some embodiments of the invention, provided herein is a microarray comprising a substrate; a plurality of probe cells formed in the substrate, wherein at least one probe cell includes a linker; and a probe cell separation area. In addition, in some embodiments, the microarray may include a molecular probe coupled to the linker. Related methods are also described herein.

Abstract: Disclosed herein are molecules that include a deoxyribonucleic acid (DNA) covalently bonded to a protein and uses thereof.

Abstract: Compositions comprise nonionic fluorinated polymeric surfactants and solvent. The solvent comprises: at least one of a polyol or polyol ether, wherein the polyol and polyol ether have from 2 to 10 carbon atoms; and at least one monohydroxy alcohol, ether, or ketone having from 1 to 4 carbon atoms, or a mixture thereof, wherein the solvent is capable of at least one of solubilizing or displacing brine or condensate in the hydrocarbon-bearing clastic formation. Embodiments of the compositions are useful in recovery of hydrocarbons from hydrocarbon-bearing clastic formations that contain brine and/or condensate.

Abstract: An oilfield treatment method is given that uses fluids that contain surfactants used as foamers and/or viscosifiers such that the fluids pass the Alberta Energy and Utilities Board Directive 27 requirements for low toxicity to certain bioluminescent bacteria. Such fluids may be used in oilfield treatments, for example drilling and stimulation, near fresh water aquifers. The surfactants are certain non-ionic surfactants that are not aromatic, or certain amphoteric surfactants (that can be neutral), or certain zwitterionic surfactants, (in which both positive and negative charges are present in a single molecule so that the whole molecule is neutral).

Abstract: An aqueous, viscoelastic fluid gelled with a viscoelastic surfactant (VES) is stabilized and improved with an effective amount of an alkali earth metal oxide alkali earth metal hydroxide, alkali metal oxides, alkali metal hydroxides transition metal oxides, transition metal hydroxides, post-transition metal oxides, and post-transition metal hydroxides. These fluids are more stable and have a reduced or no tendency to precipitate, particularly at elevated temperatures. The additives may reduce the amount of VES required to maintain a given viscosity. These stabilized, enhanced, aqueous viscoelastic fluids may be used as treatment fluids for subterranean hydrocarbon formations, such as in hydraulic fracturing. The particle size of the magnesium oxide or other agent may be nanometer scale, which scale may provide unique particle charges that use chemisorption, crosslinking and/or other chemistries to associate and stabilize the VES fluids.

Abstract: The invention relates to the use of polyethylene glycol esters of fatty acids corresponding to the following formula: R1—CO—O—(CH2—CH2—O)n—OC—R2 ??(I) in which R1 and R2 independently of one another represent alkyl groups containing 7 to 23 carbon atoms, which may be saturated or unsaturated, linear or branched, and n is a number of 2 to 50, as lubricants in the processing of thermoplastics.

Abstract: A lubricant composition comprising a detergent and a base oil comprising more than about 1.6% by weight of tetracycloparaffins is disclosed. Methods of making and using the composition are also disclosed.

Abstract: A lubricant composition comprising a dispersant and a base oil comprising more than about 1.6% by weight of tetracycloparaffins is disclosed. Methods of making and using the lubricant composition are also disclosed.

Abstract: Certain NH sterically hindered amine compounds of the formula where R is a straight or branched alkyl group of from 7 to 17 carbon atoms and where n is from 6 to 18 are suitable for use as stabilizers in lubricant compositions. The sterically hindered amines are non-aggressive towards fluoroelastomer O-rings or seals.

Abstract: The invention provides a lubricating composition containing: (a) a major amount of an ester of a polycarboxylic acylating agent; and (b) at least one compound from: (i) a metal hydrocarbyl dithiophosphate, or (ii) a viscosity modifier, wherein the metal hydrocarbyl dithiophosphate contains at least one hydrocarbyl group including an aryl functional group, a substituted-aryl functional group or mixtures thereof. The composition is suitable for high temperature engines, particularly a ceramic containing engine to provide at least one of increased fuel economy, decreased emissions of particulate matter, increased oxidative stability and decreased deposit formation.

Abstract: A stripping and cleaning composition for cleaning microelectronics substrates, the composition comprising: at least one organic stripping solvent, at least one nucleophilic amine, at least one non-nitrogen containing weak acid in an amount sufficient to neutralize from about 3% to about 75% by weight of the nucleophilic amine such that the stripping composition has an aqueous pH of from about 9.6 to about 10.9, said weak acid having a pK value in aqueous solution of 2.0 or greater and an equivalent weight of less than 140, at least one metal-removing compound selected from the group consisting of diethylene glycol and diethylene glycolamine, and water, and method for cleaning microelectronic substrates with these compositions.

Abstract: This invention relates to a aqueous liquid laundry composition which both cleans and conditions fabrics. The composition includes certain alcohol ethoxylates as a nonionic surfactant component, certain alkyl ether sulfates as an anionic component and a quaternary ammonium fabric softening agent. All of the foregoing are in specified proportions.

Abstract: The invention relates to liquid cleaning compositions that contain an oxidase enzyme which has a substrate within a stain.

Abstract: Neutralizing a surfactant which is comprised of an alkaline-catalyzed reaction product between a monomeric or polymeric alcohol having at least one active hydrogen group and an alkylene oxide with a fatty acid allows the cloud point of the surfactant to be adjusted.

Abstract: This invention relates to compositions containing lower (C1-C4) alcohol and a polymeric fluorosurfactant formulated for being dispensed as a foam product. More particularly, the invention relates to improved compositions formulated with polymeric fluorosurfactants with pendant perfluoroalkyl side chains of a fully fluorinated chain length of C1-C7. The compositions also relate to use for personal care, such as skin sanitizing and cleansing.

Abstract: In a composition for removing a polymeric contaminant that may remain on an apparatus for manufacturing a semiconductor device and a method of removing a polymeric contaminant using the composition, the composition includes from about 5 to 10 percent by weight of a fluoride salt, from about 5 to 15 percent by weight of an acid or a salt thereof, and from about 75 to 90 percent by weight of an aqueous solution of glycol. The composition can effectively remove the polymeric contaminant from the apparatus within a relatively short period of time, and suppress damages to parts of the apparatus.

Abstract: The present disclosure generally relates to cleansing products for cleansing the skin and hair. More particularly, the present disclosure relates to liquid cleansing compositions that have a sufficient viscosity to maintain particles suspended in the cleanser, but that may also be used with suitable dispensers, such as pump foam dispensers, to generate foam.

Abstract: This invention provides a method for treating a subject afflicted with a fear-related disorder comprising administering to the subject a therapeutically effective amount of a gastrin-releasing peptide receptor agonist. This invention further provides a method for inhibiting in a subject the onset of a fear-related disorder resulting from exposure to a traumatic experience comprising administering a prophylactically effective amount of a gastrin-releasing peptide receptor agonist to the subject prior to and/or following the traumatic experience.

Abstract: Methods of treating a mammal at risk for ischemia-reperfusion injury are provided. The methods comprise administering an adrenomedullin binding protein-1 (AMBP-1) to the mammal in sufficient amount to reduce the injury. Also provided are methods of treating a mammal at risk for ischemia-reperfusion injury to the bowel. The methods comprise administering adrenomedullin to the mammal in sufficient amount to reduce the injury.

Abstract: Certain aspects of the present invention provide artificial polypeptides containing one or more unnatural amino acids and methods for producing and using the artificial polypeptides.

Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with Alzheimer's Disease. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.

Abstract: Regeneration of a lesioned CNS axon of mature neuron, determined to be subject to regeneration inhibition by endogenous cJun-N-terminal kinase (JNK), is promoted by contacting the neuron with an exogenous JNK inhibitor at a concentration sufficient to partially inhibit the JNK, and thereby promote a resultant regeneration of the axon.

Abstract: A protein is efficiently nitrosylated with nitrogen monoxide by merely mixing S-nitrosoglutathione as a nitrogen monoxide donor with a protein solution containing a stabilizing agent comprising at least one compound or a combination of plural compounds selected from an N-acetylamino acid, a fatty acid, and a fatty acid salt. The method that enables efficient NO addition to a cysteine residue in un-nitrosylated protein without changing the structure of protein and hence provides NO to a living organism.

Abstract: Disclosed is the preparation and pharmaceutical use of substituted arylalcanoic acid derivatives of Formula I, wherein ring A, ring B, R1, R2, R3, R4, R5, X, Alk1, Alk2, Ar1, and Ar2 are as defined in the specification. These compounds, as selective agonists activating peroxisome proliferator-activated receptors (PPAR), in particularly the RXR/PPARalpha, RXR/PPARgamma, and RXR/PPARdelta heterodimers, are useful in the treatment and/or prevention of type 2 diabetes and associated metabolic syndrome such as hypertension, obesity, insulin resistance, hyperlipidemia, hyperglycemia, hypercholesterolemia, atherosclerosis, coronary artery disease, and other cardiovascular disorders with improved side effects profile commonly associated with conventional PPARgamma agonists.

Abstract: The present invention relates to a newly identified receptor belonging to the superfamily of G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptor. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides.

Abstract: This invention discloses compositions of chloroquine-coupled active agents, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the active agent is delivered, thereby reducing the overall dosage needed. The compositions comprise a chloroquine substance coupled to an active agent directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing active agents for therapeutic or other medical uses.

Abstract: Medium-chain length fatty alcohols such as octanol, decanol, dodecanol, or analogues thereof can be used as a stimulator of hematopoiesis, hematopoietic stem cell proliferation, and/or proliferation of one or more of the progenitors of red or white blood cells (e.g., erythrocyte, leukocyte, neutrophil, granulocyte, megakaryocyte, or any combination thereof). It also relates to the treatment of myelosuppression; in particular, this includes the treatment of anemia and/or neutropenia associated with chemotherapy and/or radiotherapy. Moreover, anemia arising from chronic renal failure or treatment of HIV-infected patients with AZT (zidovudine), or other inhibitors of reverse transcriptase, can be treated. Furthermore, neutropenia arising from infections, hematologic diseases, or nutritional deficiencies can be treated. It also relates to reducing drug toxicity and enhancing drug efficiency.

Abstract: The object of the present invention is to provide an oligopeptide having hair growth promoting activity. The present invention provides an oligopeptide which is represented by the formula (I): X1-X2-X3-X4-X5-X6-X7, or the like wherein X1 represents an amino acid residue such as Ser, X2 represents an amino acid residue such as Ile, X3 represents an amino acid residue such as Glu, X4 represents an amino acid residue such as Gln, X5 represents an amino acid residue such as Ser, X6 represents the amino acid residue Cys to which a modifying group containing a carbonyl group binds, or the amino acid residue Lys to which a modifying group containing a carbonyl group binds, and X7 represents an amino acid residue such as Glu or Ala.

Abstract: The present invention relates to novel depsipeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel depsipeptide compounds and intermediates used in producing these compounds.

Abstract: The present invention relates to crystals of phosphorylated Aurora-A kinase fragment alone and in complex with a ligand, amino acid residues 1-43 of human TPX2. This invention also relates to methods for designing and selecting ligands, in particular allosteric inhibitors of Aurora-A, that bind to the Aurora-A kinase and their use. Further, the present invention relates to certain indene and indole derivatives. The present invention relates to crystals of phosphorylated Aurora-A kinase alone and in complex with a ligand, amino acid residues 1-43 of human TPX2. This invention also relates to methods for designing and selecting ligands that bind to the Aurora-A kinase and their use. Further, the present invention relates to certain indene and indole derivative.

Abstract: A muscle growth regulating factor includes polynucleotide and polypeptide sequences, promoter sequences, constructs comprising the sequences, and compositions for regulating muscle growth and treating diseases associated with muscle growth. The present sequences can be used in identifying animals with altered muscle mass, and for selective breeding programs to produce animals with altered muscle mass.

Abstract: This invention relates to FSH or a FSH variant containing an alpha and beta subunit contained in formulations, and articles of manufacture. The invention provides advantageous new proteins and nucleic acids, multi-use pharmaceutical solutions, formulations and products of said proteins and nucleic acids where none approved for commercial use had previously existed having such extended use indications. These products are particularly useful in therapeutic regimens for increasing serum levels of FSH or a FSH variant over a period of treatment.

Abstract: Novel compositions and methods of treating and preventing a viral infection are provided. A method of blocking a viral infection facilitated by a serine proteolytic (SP) activity is disclosed, which involves administering to a subject suffering or about to suffer from a viral infection a therapeutically effective amount of a substance having serine protease inhibitory activity or serpin activity. Among the substances found to be useful are ?1-antitrypsin (AAT), peptide derivatives from the carboxy terminal end of AAT and synthetic drugs mimicking the action of such substances. The invention is particularly well suited for checking a viral infection mediated by members of herpesviridae family.

Abstract: A method for modulating hematopoietic stem cells and treating a hematologic disease in a mammal comprising administering intranasally a therapeutically effective amount of a PTH formulation. The PTH formulation may contain teriparatide.

Abstract: Human ?-defensins are inhibitors of interleukin-1? post transitional processing and release. Interleukin-1? is a key cytokine involved in the initiation and amplification of the inflammatory process, including the inflammation of diseases such as Crohn's Disease and Ulcerative Colitis. Particularly, human neutrophil defensin-1(HNP-1) produced mainly by neutrophils, and human ?-defensin 5(HD-5) produced by Paneth cells has been found to block interleukin-1? post transitional processing and release. Thus, a pharmaceutical composition and method for treating inflammation in the mammalian tissues is herein disclosed. The pharmaceutical composition is a therapeutic supplementation of a metabolic pathway to reduce inflammation comprising a human ?-defensins in a therapeutically effective amount or an amide, ester or salt thereof and a pharmaceutically effective carrier.

Abstract: The present invention provides a novel protein encoded by the KCNC1 gene and discloses the differential expression of the gene KCNC1 coding for KCNC1 proteins in specific brain regions of Alzheimer's disease patients. Based on this finding, the invention provides a method for diagnosing or prognosticating Alzheimer's disease in a subject, or for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using the KCNC1 gene and its corresponding gene products. A method of screening for modulating agents of neurodegenerative diseases is also disclosed.

Abstract: Methods and compositions for the sustained release of treatment agents to treat an occluded blood vessel and affected tissue and/or organs are disclosed. Porous or non-porous bioabsorbable glass, metal or ceramic bead, rod or fiber particles can be loaded with a treatment agent, and optionally an image-enhancing agent, and coated with a sustained-release coating for delivery to an occluded blood vessel and affected tissue and/or organs by a delivery device. Implantable medical devices manufactured with coatings including the particles or embedded within the medical device are additionally disclosed.

Abstract: Chimeric polypeptides of relaxin-3, prepropolypeptides thereof, polynucleotides encoding such polypeptides, and associated expression vectors and host cells are described. The polypeptides may be used to prepare receptor-ligand complexes with GPCR135 or GPCR142, which may be used in assay methods.

Abstract: The methodologies of the present invention demonstrate that a critical balance between pro- and anti-amyloidogenic molecules exists that regulates amyloid formation and cell death in Alzheimer's disease and Parkinson's disease. ?-Synuclein, the non-amyloidogenic homologue of ?-synuclein, is a negative modulator of ?-synuclein and A? aggregation, having neuroprotective properties against ?-synuclein and A? neurotoxicity and that ?-synuclein and therapeutic agents derived therefrom block amyloidogenesis and neurodegeneration in vivo. The method of the present invention establishes that ?-synuclein blocks A? aggregation either by direct inhibition of A? amyloidogenesis or indirectly via either ?-synuclein or its 35 a.a. NAC region, inferring neuroprotective characteristics within the effected cells.

Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

Abstract: The biological activity of nucleic acid ligand is regulated (i.e. enhanced or inhibited) in vivo to produce a desired biological effect. This is accomplished through the administration of a modulator, or regulator, that changes the binding of the nucleic acid ligand for its target or that degrades or otherwise cleaves, metabolizes or breaks down the nucleic acid ligand while the ligand is still exerting its effect. Modulators of the present invention can be administered in real time as needed based on various factors, including the progress of the patient, as well as the physician's discretion in how to achieve optimal therapy. Thus, this invention provides for the first time a regulatable therapeutic regime in the course of nucleic acid ligand therapy.

Abstract: Members of the TGF-? superfamily and peptide fragments based on member proteins are employed to purify solutions containing member proteins or as therapeutics.

Abstract: A substance including the chemical structures of bicyclo[3.2.1]octan or the chemical structures of kaurene for the use in a dietary supplementation or as a constituent in a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome. The unique chemical structures of bicyclo[3.2.1]octan alone or in a kaurene structure provides the substances, such as e.g. steviol, isosteviol and stevioside with the capability of enhancing or potentiating the secretion of insulin in a plasma glucose dependent manner. The substances including these unique chemical structures also have the capability of reducing the glucagon concentration in the blood and/or lowering the blood pressure thereby providing a self-regulatory treatment system for non-insulin dependent diabetes mellitus and/or hypertension.

Abstract: The present invention provides for methods of inhibiting hair growth, comprising decreasing the level of TRPS1 mRNA and/or protein in hair follicle cells of a subject. The present invention also provides for methods of promoting hair growth, comprising increasing the level of TRPS1 mRNA and/or protein in hair follicle cells of a subject. The level of TRPS1 may be decreased or increased either directly, for example by introducing, into a hair follicle cell, a TRPS1 mRNA or protein. Alternatively, the level of TRPS1 may be decreased or increased indirectly, by providing an agent that results in decreased or increased expression of an endogenous TRPS1 gene. The invention also provides for transgenic animals with aberrancies in TRPS1 expression, and for assay systems (including transgenic animals and cell-based systems) that may be used to identify agents that decrease or increase TRPS1 expression.